Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence

Fig. 3

Mean change from baseline in total cholesterol (a), HDL-C (b), and LDL-C (c). HDL-C: High-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol. Studies included [13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30]: Group 1 (12 weeks): Shetty et al. [13], Thacker et al. [14], Joshi et al. [15], Bhattacharyya et al. [16]; Group 2 (24 weeks): Saboo et al. [17], Joshi et al. [18], Chhaya et al. [19], Mohit et al. [20], Kaul et al. [21], Goyal et al. [22]; Group 3 (27 weeks): Chatterjee et al. [23]; Group 4 (36 weeks): Joshi et al. [24]; Group 5 (40 weeks): Chatterjee et al. [25]; Group 6 (52 weeks): Joshi et al. [26], Aneja et al. [27], Maheshwari et al. [28], Chatterjee et al. [29]; Group 7 (58 weeks): Chatterjee et al. [30]. Mean total cholesterol calculation: data not available for Joshi et al. [15], Saboo et al. [17], Joshi et al. [18], Goyal et al. [22], Joshi et al. [24]. Mean HDL-C calculation: data not available for Joshi et al. [15], Saboo et al. [17], Joshi et al. [18], Chhaya et al. [19], Goyal et al. [22], Maheshwari et al. [28], Chatterjee et al. [29]. Mean LDL-C calculation: data not available for Joshi et al. [15], Saboo et al. [17], Joshi et al. [18], Goyal et al. [22], Aneja et al. [27]

Back to article page